Navigation Links
MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease

- Numax Achieves Primary Endpoint Among High-Risk Infants Versus Current Standard of Care and Shows Reduction of Medically Attended Outpatient RSV- Related Lower Respiratory Infections -

TORONTO, May 08, 2007 /PRNewswire-FirstCall/ -- MedImmune, Inc. today announced positive results from a large prospective trial conducted for prevention of respiratory syncytial virus (RSV). The trial compared motavizumab, the investigational monoclonal antibody (MAb) also known as Numax(R), with Synagis(R) (palivizumab), the standard of care for preventing RSV hospitalization in high-risk infants. In the Phase 3 study involving 6,635 pre-term infants at high risk for RSV, with a primary endpoint of non- inferiority, motavizumab demonstrated overall 26-percent fewer RSV hospitalizations compared with Synagis (p<0.01 for non-inferiority). Additionally, motavizumab demonstrated a statistically significant 50 percent reduction in the incidence of RSV-specific medically attended outpatient lower respiratory infections (LRIs) (p<0.01) compared with Synagis. These findings were presented today in a poster entitled, Phase 3 Trial of Motavizumab, an Enhanced Potency RSV-Specific MAb for the Prevention of Serious RSV Disease in High-Risk Infants, at the Pediatric Academic Societies' Annual Meeting in Toronto, Canada.

"As RSV continues to be the leading cause of lower respiratory tract infections in infants in the United States, we are very encouraged by the results of this Phase 3 trial, which suggest that motavizumab may help to reduce the chance that our most vulnerable babies will have serious RSV disease," said Edward M. Connor, M.D., chief medical officer and executive vice president. "Data from the study showed that motavizumab was statistically superior to Synagis for the secondary endpoint of outpatient medically attended LRI caused by RSV, and thus may reduce the overall burden of RSV disease compared to the current stan
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:11/26/2014)... , Nov. 26, 2014  BioScrip ® , Inc. (NASDAQ: ... , President and Chief Executive Officer, will present at the Bank ... , , , Date: , , , Wednesday, December ... 2:50 p.m. EST , , , , Location: , , ... About BioScrip, Inc. BioScrip, Inc. ...
(Date:11/26/2014)... RADNOR, Pa. , Nov. 26, 2014 ... dedicated to the development of innovative transdermal synthetic cannabinoid ... the Piper Jaffray 26th Annual Healthcare Conference 2014. The ... the New York Palace in New York ... , will present at 4:50 pm on Tuesday, December ...
(Date:11/26/2014)... , Nov. 26, 2014  Aridis Pharmaceuticals, ... produce novel therapies for infectious diseases, announced today ... an internationally recognized key opinion leader in the ... scientific advisory board. Founder and Chief ... "We believe Dr. Opal,s extensive experience investigating bacterial ...
Breaking Medicine Technology:Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3
... A new study by researchers at Harvard ... vitamins, including B6, B12, and folic acid, lower risk ... leading causes of vision loss among older Americans. These ... fatty acids and phytosterols, are also contained in the ...
... and PCPs Vary in Their Prescribing Patterns of Levodopa/Carbidopa ... Decision ResourcesWALTHAM, Mass., March 4 Decision Resources, one ... on pharmaceutical and healthcare issues, finds that second-line patient ... 14.1 percent to 35.2 percent since last year,s report. ...
Cached Medicine Technology:Harvard Study Shows Folic Acid, B Vitamins in Animi-3(R) May Prevent Vision Loss 2Teva's Azilect Use Dramatically Increases in Second-Line Therapy for the Treatment of Parkinson's Disease 2Teva's Azilect Use Dramatically Increases in Second-Line Therapy for the Treatment of Parkinson's Disease 3
(Date:11/27/2014)... (PRWEB) November 28, 2014 This is ... of the global Bronchoscopes industry with a focus on ... the market status of the Bronchoscopes manufacturers and is ... and individuals interested in the industry. , Firstly, the ... its definition, applications and manufacturing technology. Then, the report ...
(Date:11/27/2014)... The American Society for Clinical Pathology (ASCP) ... in honor of World AIDS Day 2014. On Nov. 25, ... cure.” icon and infographic designed to generate public awareness about ... HIV. , ASCP has asked members to replace their Facebook, ... Get Tested. Find a cure.” icon and share the accompanying ...
(Date:11/27/2014)... 27, 2014 According to a recent ... looking to break into the surgical robotics market ... other than the MIS field dominated by Intuitive. These ... U.S. surgical robotics market by 2020. , “The ... Kamran Zamanian, CEO and President of iData. “System sales ...
(Date:11/27/2014)... November 27, 2014 In a ... allot to sleep has lessened, and due to ... the quality of sleep has eroded. According to ... on the job (Reference: http://www.webmd.com/sleep-disorders/features/sleep-deprivation-workplace ). This ... index by an incalculable amount, leading not only ...
(Date:11/27/2014)... PITTSBURGH, PA (PRWEB) November 27, 2014 ... suffer the embarrassing side effects of urinary incontinence," said ... to it and developed this specialized accessory to prevent ... developed the Incontinence to absorb urine leakage. This prevents ... wearer from potential embarrassment. The pad ensures that the ...
Breaking Medicine News(10 mins):Health News:Bronchoscopes Industry 2019 Forecasts for Global and China Region in New Research Report at ReportsnReports.com 2Health News:Bronchoscopes Industry 2019 Forecasts for Global and China Region in New Research Report at ReportsnReports.com 3Health News:ASCP Launches Social Media Campaign in Honor of World AIDS Day 2Health News:U.S. Robotic Surgery Market Set to Diversify and Grow: Intuitive Surgical’s ‘da Vinci’ Robot Revenues to Increasingly Rely On Procedures and Services 2Health News:Research Shows Surprising Number of US Workers Affected by Lack of Sleep 2
... 21 Omnicell,Inc. (Nasdaq: OMCL ), a leading ... results for its first quarter ended,March 31, 2008., ... totaled $62.1,million, up $4.1 million or 7.2% from the ... from the first quarter of 2007., First quarter ...
... MDS Board, TORONTO, April 21 /PRNewswire-FirstCall/ - MDS ... and services to the global life,sciences markets, today announced ... William Dempsey, former Executive Vice-President,of Abbott Laboratories, have been ... both Greg and Bill and look forward to benefiting ...
... 6 millimeters in diameter appear more likely to be ... the April issue of Archives of Dermatology, one of ... guidelines currently used by dermatologists to screen for melanoma ... to screen for melanoma, according to background information in ...
... Insurance,Holdings, Inc. ("EIHI") (Nasdaq: EIHI ) today ... (Excellent) financial strength ratings of EIHI members,Eastern Alliance ... Company ("ELH") and upgraded the outlook for EAIG ... specializing in workers,compensation. A.M. Best reaffirmed a stable ...
... also finds survival rates similar, no matter when admission ... to heart attack patients who arrive at hospitals during ... hours tend to receive faster and more comprehensive care, ... affect in-hospital death rates of heart attack patients, said ...
... Successful Transition, BIRMINGHAM, Ala., April 21 ... Hayek has been named president and,chief executive officer ... executive officer, Mike Snow, is resigning his position ... as an advisor on the company,s,board of directors., ...
Cached Medicine News:Health News:Omnicell Announces First Quarter 2008 Results 2Health News:Omnicell Announces First Quarter 2008 Results 3Health News:Omnicell Announces First Quarter 2008 Results 4Health News:Omnicell Announces First Quarter 2008 Results 5Health News:Omnicell Announces First Quarter 2008 Results 6Health News:Omnicell Announces First Quarter 2008 Results 7Health News:Omnicell Announces First Quarter 2008 Results 8Health News:Omnicell Announces First Quarter 2008 Results 9Health News:Omnicell Announces First Quarter 2008 Results 10Health News:Omnicell Announces First Quarter 2008 Results 11Health News:MDS Appoints Two New Directors 2Health News:MDS Appoints Two New Directors 3Health News:Larger skin lesions appear more likely to be melanomas 2Health News:Eastern Alliance Insurance Group and Eastern Life and Health Insurance Company Announce Affirmation of A- (Excellent) A.M. Best Ratings and a Positive Outlook for Eastern Alliance Insurance Group 2Health News:Eastern Alliance Insurance Group and Eastern Life and Health Insurance Company Announce Affirmation of A- (Excellent) A.M. Best Ratings and a Positive Outlook for Eastern Alliance Insurance Group 3Health News:Off-Hours Heart Patients Less Likely to Get Angioplasty 2Health News:SCA Names Andrew Hayek as New President and CEO 2
Used for endobronchial blockade of the left or right lung for procedures which require one-lung ventilation. Supplied sterile in peel-open packages. Intended for one-time use....
... can establish an airway (up to 7.2 mm ... used for fast and safe emergency airway access., ... and a 7.2 mm I.D. airway within seconds. ... ventilation. A suction catheter can be introduced through ...
... Howland lock handle - Chrome-plated brass. Rusch ... standard laryngoscope handles that are compatible with ... standards. The designs of these handles have ... use the world over to minimize maintenance ...
... Standard Chrome plated brass. Available ... a reliable tradition of high quality ... with all standard/conventional blades manufactured to ... these handles have been continually refined ...
Medicine Products: